DE69920011D1 - Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff - Google Patents

Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff

Info

Publication number
DE69920011D1
DE69920011D1 DE69920011T DE69920011T DE69920011D1 DE 69920011 D1 DE69920011 D1 DE 69920011D1 DE 69920011 T DE69920011 T DE 69920011T DE 69920011 T DE69920011 T DE 69920011T DE 69920011 D1 DE69920011 D1 DE 69920011D1
Authority
DE
Germany
Prior art keywords
zephalitis
venezolanian
equine
vaccine
horse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920011T
Other languages
English (en)
Other versions
DE69920011T2 (de
Inventor
Alice Marie Bennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Application granted granted Critical
Publication of DE69920011D1 publication Critical patent/DE69920011D1/de
Publication of DE69920011T2 publication Critical patent/DE69920011T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE69920011T 1998-05-29 1999-05-05 Rekombinantes virus-vakzin gegen das virus der venezolanischen equinen encephalitis Expired - Lifetime DE69920011T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9811433 1998-05-29
GB9811433A GB2337755B (en) 1998-05-29 1998-05-29 Virus vaccine
PCT/GB1999/001387 WO1999063098A1 (en) 1998-05-29 1999-05-05 Recombinant venezuelan equine encephalitis virus vaccine

Publications (2)

Publication Number Publication Date
DE69920011D1 true DE69920011D1 (de) 2004-10-14
DE69920011T2 DE69920011T2 (de) 2005-09-15

Family

ID=10832820

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920011T Expired - Lifetime DE69920011T2 (de) 1998-05-29 1999-05-05 Rekombinantes virus-vakzin gegen das virus der venezolanischen equinen encephalitis

Country Status (14)

Country Link
US (2) US6936257B1 (de)
EP (1) EP1084261B8 (de)
AR (1) AR020080A1 (de)
AT (1) ATE275631T1 (de)
AU (1) AU3834999A (de)
BR (1) BR9910814A (de)
CA (1) CA2329133C (de)
DE (1) DE69920011T2 (de)
DK (1) DK1084261T3 (de)
ES (1) ES2224655T3 (de)
GB (1) GB2337755B (de)
MX (1) MXPA00011708A (de)
PT (1) PT1084261E (de)
WO (1) WO1999063098A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
CA2401974C (en) 2000-03-02 2013-07-02 Emory University Dna expression vectors and methods of use
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
CA2454959C (en) 2001-03-08 2018-07-10 Bernard Moss Mva expressing modified hiv envelope, gag, and pol genes
EP1528677B1 (de) * 2003-10-30 2006-05-10 Agilent Technologies, Inc. Akustisch gekoppelter Dünnschicht-Transformator mit zwei piezoelektrischen Elementen, welche entgegengesetzte C-Axen Orientierung besitzten
EP2626078A1 (de) 2007-02-23 2013-08-14 Her Majesty The Queen, In Right Of Canada, As Represented by the Minister of National Defence Inokulation rekombinanter viraler Vektoren zur schnellen Präexpositionsvorbeugung und Postexpositionsschutz gegen alphavirusinduzierte Encephalitide
EP2440251A4 (de) * 2009-06-09 2013-01-16 Defyrus Inc Verabreichung von interferon zur prophylaxe gegen oder zur behandlung von krankheitserregenden infektionen
EP2675473A1 (de) 2011-02-15 2013-12-25 Immune Design Corp. Verfahren zur verbesserung von immunogenspezifischen immunreaktionen durch vektorisierte impfstoffe
EP2694099B1 (de) 2011-04-08 2019-10-16 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
WO2013151567A1 (en) * 2012-04-04 2013-10-10 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research Institute Of Infectious Diseases Equine encephalitis virus vaccines and methods of using thereof
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
SG10201707449TA (en) * 2012-11-05 2017-10-30 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
SG11201606625RA (en) 2014-02-14 2016-09-29 Immune Design Corp Immunotherapy of cancer through combination of local and systemic immune stimulation
CA2955015A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
PL3407910T3 (pl) 2016-01-29 2022-08-16 Bavarian Nordic A/S Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
FI3596116T3 (fi) 2017-03-16 2023-11-09 Alpine Immune Sciences Inc Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
NZ756395A (en) 2017-03-16 2024-01-26 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
EP3601367A4 (de) 2017-03-30 2020-09-16 The University of Queensland Chimäre moleküle und verwendungen davon
MA50360A (fr) 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
KR20200085777A (ko) 2017-10-18 2020-07-15 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 icos 리간드 면역조절 단백질 및 관련 조성물 및 방법
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN113544144A (zh) 2018-09-19 2021-10-22 高山免疫科学股份有限公司 变体cd80融合蛋白和相关构建体的方法和用途
AU2019389151A1 (en) 2018-11-30 2021-06-10 Alpine Immune Sciences, Inc. CD86 variant immunomodulatory proteins and uses thereof
JP2022529059A (ja) 2019-04-17 2022-06-16 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド（ｉｃｏｓｌ）融合タンパク質の方法および使用
CN116903727A (zh) 2020-05-08 2023-10-20 高山免疫科学股份有限公司 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法
KR20240019124A (ko) 2021-05-07 2024-02-14 알파인 이뮨 사이언시즈, 인코포레이티드 Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine

Also Published As

Publication number Publication date
GB2337755B (en) 2003-10-29
AR020080A1 (es) 2002-04-10
GB9811433D0 (en) 1998-07-22
EP1084261B1 (de) 2004-09-08
AU3834999A (en) 1999-12-20
DE69920011T2 (de) 2005-09-15
ES2224655T3 (es) 2005-03-01
CA2329133A1 (en) 1999-12-09
WO1999063098A1 (en) 1999-12-09
EP1084261B8 (de) 2004-12-15
MXPA00011708A (es) 2005-10-13
USRE41745E1 (en) 2010-09-21
PT1084261E (pt) 2005-01-31
DK1084261T3 (da) 2005-01-17
EP1084261A1 (de) 2001-03-21
ATE275631T1 (de) 2004-09-15
CA2329133C (en) 2011-07-12
US6936257B1 (en) 2005-08-30
GB2337755A (en) 1999-12-01
BR9910814A (pt) 2001-02-13

Similar Documents

Publication Publication Date Title
DE69920011D1 (de) Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff
NO2010013I1 (no) Rekombinant FSH-CTP
NO982097L (no) Peptider
NO982098L (no) Peptider
DE59901560D1 (de) Retrograder tibianagel
DE59902874D1 (de) Buchsenkontakt
DE59907306D1 (de) Fadenchangierung
DE59906931D1 (de) Exzenterzahnradgetriebe
DE69933647D1 (de) Rekombinante lysophosphatidsäure - phosphatase.
ATE262513T1 (de) Benzoylpyridazine
DE59903966D1 (de) Exzenterzahnradgetriebe
DE59908769D1 (de) N-arylsulfonyl-aminosäure-omega-amide
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
DE59908057D1 (de) Underdruckhandhabungseinrichung
FR2791348B1 (fr) POLYPEPTIDE Npt2B
DE59807217D1 (de) Nadellager
DK0862850T3 (da) Mejetærsker
DE59808995D1 (de) Endomikroskopsystem
DE59903616D1 (de) Rollenwicklerwalze
DE59900612D1 (de) Dispersionsazofarbstoffmischungen
DE59902088D1 (de) Achrathermer Reimager
NO20012283D0 (no) Koblede peptider
DE59910491D1 (de) Umlufttrockner
DE59910289D1 (de) Friktionsdrallvorrichtung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE SECRETARY OF STATE FOR DEFENCE, SALISBURY, GB

8364 No opposition during term of opposition